L-propionylcarnitine effect on postexercise and postischemic hyperemia in patients affected by peripheral vascular disease.
The hemodynamic effect of L-propionylcarnitine (LPC) administered intravenously was evaluated in a double-blind, randomized, three-period crossover study in 12 men (aged sixty to seventy-five years) with Leriche-Fontaine stage II peripheral arterial disease of lower limbs. At baseline, maximum working capacity of each patient was determined by a standardized ergometric test. This test was repeated at 80% of each patient's maximum working capacity before and after intravenous administration of LPC. Each patient received three single doses of 300 mg, 600 mg, and 1200 mg of LPC with a two-day rest period between them. Hemodynamic variables measured by strain-gauge plethysmography were: peak blood flow, peak flow time, and halftime and total time of hyperemia both after exercise and after induction of ischemia (with an occlusion cuff). LPC administration significantly shortened the halftime as well as the total time of hyperemia after exercise and after ischemia. With the two highest doses, LPC shortened the peak flow time after exercise. The peak blood flow after exercise and after ischemia increased, but this increase did not reach statistical significance. The results obtained indicate that LPC improves circulatory reserve of the ischemic limb and has no effect on heart rate and arterial blood pressure. No adverse events were reported. The effect of LPC on the hyperemic response to stress, mainly on halftime of hyperemia, is possibly due to a drug-induced increase of adenosine triphosphate utilization by the ischemic tissues.
Corsi
C
C
Istituto S. Chiara, Firenze, Italy.
Pollastri
M
M
Marrapodi
E
E
Leanza
D
D
Giordano
S
S
D'Iddio
S
S
D000368:Aged; D001783:Blood Flow Velocity / Q000187:drug effects; D002331:Carnitine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D006940:Hyperemia / Q000209:etiology / Q000503:physiopathology*; D007275:Injections, Intravenous; D007383:Intermittent Claudication / Q000188:drug therapy* / Q000503:physiopathology; D007511:Ischemia / Q000503:physiopathology; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion
C003223:propionylcarnitine; D002331:Carnitine